VTRS$19.040.86%-0.165
After Hours: 18.91-0.13 -0.66%
Viatris Inc (VTRS)
Date: 2026-10-30 16:00O: 19.29H: 19.51L: 19.00C: 19.04Vol: 8.785M
Viatris Inc stock is traded at $19.04, with a volume of 8,784,907. It is down -0.86% in the last 24 hours and up +7.42% over the past month. Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Previous Close:
$19.20
Open:
$19.29
24h Volume:
8,784,907
Relative Volume:
1.00
Market Cap:
$21.86B
Revenue:
$14.57B
Net Income/Loss:
-$296.50M
P/E Ratio:
-
EPS:
-$0.259
Net Cash Flow:
$1.64B
1W Performance:
+5.75%
1M Performance:
+7.42%
6M Performance:
+27.41%
1Y Performance:
+83.74%
1-Day Range:
$19.00$19.51
1-Week Range:
$18.11$19.51
52-Week Range:
$9.92$19.51
Viatris Inc Stock (VTRS) Company Profile
Compare VTRS vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS Viatris Inc | $19.04 | $21.86B | $14.57B | -$296.50M | $1.64B | -$0.259 |
 TAK Takeda Pharmaceutical Co Adr | $20.91 | $66.81B | $29.91B | $1.30B | $3.49B | $0.4056 |
 TEVA Teva Pharmaceutical Industries Ltd Adr | $42.09 | $49.09B | $17.53B | $1.58B | $444.18M | $1.35 |
 HLN Haleon Plc Adr | $8.66 | $38.08B | $14.54B | $2.22B | $2.58B | $0.4871 |
 ZTS Zoetis Inc | $79.72 | $32.94B | $9.51B | $2.64B | $2.14B | $6.04 |
 UTHR United Therapeutics Corp | $598.72 | $25.68B | $3.17B | $1.29B | $1.01B | $27.09 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Viatris Inc Stock (VTRS) Insider Trading
- Paul CampbellJun 25 '26Officer
- Transaction
- Proposed Sale
- Cost
- $16.17
- #Shares
- 50,076
- Value ($)
- 809,678
- #Shares Total
- 0
- Campbell PaulJun 25 '26See Remarks
- Transaction
- Sale
- Cost
- $16.17
- #Shares
- 50,076
- Value ($)
- 809,784
- #Shares Total
- 316,212
- Le Goff CorinneApr 15 '26Chief Commercial Officer
- Transaction
- Option Exercise
- Cost
- $0.00
- #Shares
- 42,988
- Value ($)
- 0
- #Shares Total
- 122,558
- Campbell PaulMar 23 '26See Remarks
- Transaction
- Sale
- Cost
- $13.28
- #Shares
- 21,350
- Value ($)
- 283,539
- #Shares Total
- 366,288
- Paul CampbellMar 23 '26Officer
- Transaction
- Proposed Sale
- Cost
- $13.28
- #Shares
- 21,350
- Value ($)
- 283,508
- #Shares Total
- 0
- MARK RICHARD AMar 06 '26Director
- Transaction
- Option Exercise
- Cost
- $0.00
- #Shares
- 24,835
- Value ($)
- 0
- #Shares Total
- 116,145
- Campbell PaulMar 06 '26See Remarks
- Transaction
- Option Exercise
- Cost
- $0.00
- #Shares
- 28,974
- Value ($)
- 0
- #Shares Total
- 398,956
- Smith Scott AndrewMar 06 '26Chief Executive Officer
- Transaction
- Option Exercise
- Cost
- $0.00
- #Shares
- 130,701
- Value ($)
- 0
- #Shares Total
- 1,374,576
- HIGGINS MELINA EMar 06 '26Director
- Transaction
- Option Exercise
- Cost
- $0.00
- #Shares
- 24,835
- Value ($)
- 0
- #Shares Total
- 146,048
- Groothuis Leo FransMar 06 '26Director
- Transaction
- Option Exercise
- Cost
- $0.00
- #Shares
- 24,835
- Value ($)
- 0
- #Shares Total
- 63,567
